---
layout: post
title: "Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:55:59 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-13767
original_published: 2023-06-28 00:00:00 +0000
significance: 8.00
---

# Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 28, 2023 00:00 UTC
**Document Number:** 2023-13767

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act." This draft guidance describes FDA's interpretation of, and policies concerning, the statutory prohibition on wholesaling for certain compounded drugs. This draft guidance also describes examples of how FDA intends to apply the statutory wholesaling provision.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/28/2023-13767/prohibition-on-wholesaling-under-section-503b-of-the-federal-food-drug-and-cosmetic-act-draft)
- API: https://www.federalregister.gov/api/v1/documents/2023-13767

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
